Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Jacob Hirdler"'
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/9a1d69011c084936ad3300b7020a2677
Autor:
Xin Liu, Haidong Dong, Sean Park, Curtis Ruegg, Fabrice Lucien-Matteoni, Michelle Hsu, Jacob Hirdler, Roxane Lavoie, Kevin Pavelko, Jacob Orme, Lou Hawthorne, John Dodgson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/474b0ea893bf41168d1e1f93860dbec3
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/3030392f862d491da8c71ca26b2a4ed8
Autor:
Reza Nabavizadeh, Rodrigo Rodrigues Pessoa, Zesheng An, Joanina Gicobi, Susan Harrington, Henan Zhang, Tianxiao Xu, Jacob Hirdler, Christine Lohse, Bradley Leibovich, Haidong Dong, Fabrice Lucien
Publikováno v:
Journal of Urology. 209
Autor:
Reza Nabavizadeh, Rodrigo Rodrigues Pessoa, Zesheng An, Joanina Gicobi, Susan Harrington, Henan Zhang, Tianxiao Xu, Jacob Hirdler, Christine Lohse, Bradley Leibovich, Haidong Dong, Fabrice Lucien
Publikováno v:
Journal of Urology. 209
Autor:
Jacob Orme, Roman Thaler, Dejie Wang, Siven Chinniah, Jacob Hirdler, Fernando Quevedo, Lance Pagliaro, Kwon Eugene, Alan Bryce, Brian Costello, Haojie Huang, Sean Park
Publikováno v:
Cancer Research. 82:397-397
NRG-1 signals through epidermal growth factor receptor (EGFR) family members. Despite promising preclinical data, HER2 blockade in prostate cancer has failed to improve outcomes in clinical trials.1-4 We have discovered a novel complex systemic role
Autor:
Henan Zhang, Ti Wen, Ying Li, Yiyi Yan, Jacob Hirdler, Whitney Barham, Cindy Liu, Joanina K. Gicobi, Fabrice Lucien-Matteoni, Haidong Dong
Publikováno v:
Cancer Research. 81:504-504
Cytotoxic T lymphocytes (CTL's) are capable of killing tumor cells throughout the body, and can be stimulated to do so by a form of immunotherapy known as PD-1 checkpoint blockade. However, the majority of patients given anti-PD-1 therapeutics do not
Autor:
Joanina K Gicobi, Xiatong Yu, Roxana S. Dronca, Xin Liu, Whitney Barham, Ti Wen, Henan Zhang, Mojun Zhu, Susan M. Harrington, Vianca Vianzon, Jacob Hirdler, Haidong Dong
Publikováno v:
The Journal of Immunology. 204:165.7-165.7
The immune response to anti-PD-1 therapy in cancer patients is not completely defined due to lack of reliable biomarkers that can determine T cell function. Bim, a member of the Bcl-2 family, was recently identified as a downstream signaling molecule